

FINDING OF NO SIGNIFICANT IMPACT FOR

Marketing Order for

Marlboro 72's Gold Pack Box

Manufactured by Philip Morris USA Inc.

The Center for Tobacco Products of the Food and Drug Administration (FDA) has carefully considered the potential environmental impacts of this action and has concluded that this action will not have a significant effect on the quality of the human environment. Therefore, an environmental impact statement is not required.

Philip Morris USA Inc. wishes to introduce one combusted, filtered cigarette product into interstate commerce for commercial distribution in the United States and submitted to FDA a substantial equivalence report to obtain marketing orders under the provisions of sections 910 and 905(j) of the Federal Food, Drug, and Cosmetic Act.

The Agency prepared the environmental assessment (EA), dated December 3, 2018, in accordance with the Council on Environmental Quality's regulations (40 CFR Part 1500) implementing the National Environmental Policy Act (NEPA) and FDA's NEPA regulations (21 CFR 25.40) to support the finding of no significant impact. The evidence supporting this finding is contained in the attached EA, which is available to the public upon request.

The EA evaluates potential environmental effects due to manufacturing, use, and disposal of the new product. No increased or new types of environmental impacts due to manufacturing are anticipated. The Agency does not foresee use of the new product would result in new or different environmental impacts. The Agency believes that the disposal of the new product is the same as the disposal conditions of other filtered, combusted cigarettes that are currently marketed in the United States. Therefore, the Agency does not foresee adverse impacts to the environment due to the proposed actions as a result of manufacturing, use and disposal of the new product.

Approved by

**Kimberly A.
Benson -S**

Digitally signed by Kimberly
A. Benson -S
Date: 2018.12.03 15:52:17
-05'00'

Kimberly Benson, Ph.D.
Director
Division of Nonclinical Science
Office of Science
Center for Tobacco Products
U.S. Food and Drug Administration